Sera Prognostics PRIME study meets efficacy endpoint at interim; enrollment stopped

SERA PROGNOSTICS, INC.

DSMB recommended stopping PRIME study enrollment after one co-primary endpoint met efficacy stopping criteria at interim.
Company adopted DSMB recommendation; will stop enrollment to focus on analyzing and reporting available data.
CEO Zhenya Lindgardt described early stop as 'unexpected' and 'encouraging,' citing consistency with prior PREVENT and AVERT studies.
The PRIME trial is pivotal for the PreTRM® test, which aims to predict preterm birth risk.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.